Wijnen, S. C. M. A. and Dimitriadis, P. and Reijers, I. L. M. and Menzies, A. M. and Long, G. V. and Wessels, L. F. A. and Blank, Christian U. (2025) Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures. CANCER IMMUNOLOGY IMMUNOTHERAPY, 74 (8): 253. ISSN 0340-7004, 1432-0851
Full text not available from this repository. (Request a copy)Abstract
Neoadjuvant combination therapy with anti-PD-1 and anti-CTLA4 agents has significantly improved long-term survival in patients with metastatic melanoma, yet not all patients respond to treatment. Responders often exhibit upregulated baseline inflammatory signatures; however, these markers capture only a single facet of the Cancer-Immunity Cycle-a comprehensive model describing the sequential steps required for effective anti-cancer immunity. To determine whether non-responsiveness to immunotherapy arises from single or multiple 'defective' steps, we analyzed in melanoma patients, treated with neoadjuvant immunotherapy, gene signatures representing each step of the cycle. Patients not achieving a major pathological response showed overall lower expression of these signatures. Among the 'immune-hot' patients, we identified a low response subgroup defective in one step ('homing-to-the-tumor,' involving CXCL9 and CXCL10), making this a promising target for improving their outcomes.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | INHIBITOR; SURVIVAL; Melanoma; Immune checkpoint inhibitors; Cancer-immunity cycle; Biomarkers; WES; RNA sequencing |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 29 Sep 2026 05:30 |
| Last Modified: | 29 Sep 2026 05:30 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67066 |
Actions (login required)
 |
View Item |
